Investment

Market growth 2024
#Biotech #Funding #GlobalData #Investment #Market reporting

Biotech funding recovery predicted for 2024

The biotech market is heading to recovery in 2024, following a marked downturn in investment in 2022 and 2023, according to healthcare industry professionals. A GlobalData survey ‘The State of the Biopharmaceutical Industry 2024’ found that more than 40% of the healthcare industry professionals surveyed globally expressed an optimistic or… Read More

#Business & Investment #News #Trending News

Deal making concept
#Clinical development #Investment #Partnership

New joint programme for clinical stage assets 

Fosun Pharma USA and Treehill Partners have formed a jointly operating vehicle for investment in clinical stage assets.  The new business will be looking for high-quality, mid- to late-stage assets, clinically focused on the US market. There will also be a focus on high quality non-US clinical… Read More

#News

EU flag
#Cancer Research UK #Drug research #Funding #Horizon Europe #Investment #UK

What’s on the horizon for UK drug discovery?

Editor Reece Armstrong provides an introduction to the Fall 2023 issue of Drug Discovery World. Find out more about the issue and how to read it. That this issue should feature a market report on the state of the United Kingdom’s drug discovery sector at the same time the country… Read More

#Exclusive Content #Opinion

#Artificial intelligence (AI) #Evozyne #Funding #Generative AI #Investment

$81 million raised to advance generative AI for drug discovery

Evozyne has closed an $81 million Series B investment round that will fund the biotech’s generative AI-powered drug discovery platform and product development. “In its first three years, Evozyne proved it could deliver novel, high-performance proteins that solve critical problems in healthcare and sustainability. Our next three years will be… Read More

#Business & Investment #News

#BioInnovation Institute #Drug discovery #Funding #Investment #Start-ups

Three therapeutics start-ups join acceleration programme

The BioInnovation Institute (BII) has welcomed three new drug discovery start-ups into its Venture Lab acceleration programme as part of its latest cohort of eight companies. The 12-month Venture Lab programme is designed to support start-up companies with business acceleration, scientific and team development, and provides… Read More

#News #Start-up Zone

#Cancer research #Funding #Investment #Oncology #Paediatrics

$4.3 million awarded to advance transcription factor drugs

Talus Bio has received $4.3 million in new grants from the National Institutes for Health (NIH) and the Washington State Andy Hill CARE Fund to advance its paediatric cancer therapeutics. The Seattle-based company received two grants totalling $2.3M from the CARE Fund to fuel the discovery of new transcription factor… Read More

#Business & Investment #News

#Business #Drug discovery #Investment #Mergers and acquisitions

Five key drug discovery deals of summer 2023

The life sciences sector has seen significant M&A activity over the last few weeks. DDW’s Diana Spencer provides an overview. BioIVT acquires PrecisionMed In July BioIVT acquired biospecimens company PrecisionMed, gaining access to, reportedly, the largest private, global repository of longitudinally collected human CSF for scientific research. “We are thrilled… Read More

#Business & Investment #Editor's Choice #News

CAR-T cells attack cancer cells
#Astellas Pharma #Cancer research #CAR-T #Cell therapy #Investment #Poseida Therapeutics #Solid tumours

Astellas invests in CAR-T cell therapy for solid tumours

Astellas Pharma will invest $50 million into Poseida Therapeutics to secure the rights to the company’s cancer CAR-T cell therapy for solid tumours, which is currently in Phase I trials. The total $50 million will include $25 million to acquire 8,333,333 shares of common stock of Poseida and a one-time… Read More

#Business & Investment #News

Great British Pounds, Investment
#ABPI #BioIndustry Association #Biologics / Biotechnology #Clarivate #Financing #Investment #UK

UK biotech financing up 29% on last quarter

The second quarter of 2023 has seen steady growth in financing activity for the UK’s life sciences sector, according to new data released by the BioIndustry Association (BIA) and Clarivate. The positive news comes soon after industry figures welcomed recent announcements to unlock new sources of capital in the City… Read More

#Business & Investment #News

Biogen head office
#ALS #Alzheimer's #Biogen #Business #Investment #Mergers and acquisitions

Biogen acquires Reata and cuts 1,000 jobs

Biogen has revealed an agreement to acquire Reata Pharmaceuticals for approximately $7.3 billion. The news follows an announcement by the company last week that it would cut around 1,000 jobs, or 11% of its workforce, to allow investment into its product pipeline. In its second quarter results, the company said… Read More

#Business & Investment #News #Trending News

#Artificial intelligence (AI) #Cell and gene therapy #Funding #Investment #Oncology #Private investment #Synthetic biology #UK

DDW Highlights podcast: New episode

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Despite the bad news for the UK life sciences industry this week that international investment dropped… Read More

#News

#Artificial intelligence (AI) #Cell and gene therapy #Funding #Investment #Oncology #Private investment #Synthetic biology #UK

This week in drug discovery (3-7 July)  

News round-up for 10-14 July by DDW Digital Content Editor Diana Spencer. Despite the bad news for the UK life sciences industry this week that international investment dropped nearly 50% in 2022, both private and public funding activity has continued apace in the wider drug discovery… Read More

#News

UK financial markets
#ABPI #Investment #Life sciences #UK #UK government

International investors abandon UK life sciences

International investors are abandoning UK life sciences as excessive revenue clawback rates start to bite, according to the latest Life Sciences Competitiveness Indicators published by the government1. The UK saw a substantial drop in the estimated value of inward life sciences foreign direct investment (FDI) in 2022 compared to 2021,… Read More

#Business & Investment #Editor's Choice #News

AI drug discovery
#AI / data analytics / healthtech / informatics #Drug discovery #Funding #Investment #Recursion

Nvidia invests $50 million into Recursion for drug AI 

Recursion, a clinical stage company decoding biology to industrialise drug discovery, has announced a $50 million investment by NVIDIA, which was executed as a private investment in public equity (PIPE).   Recursion also announced plans to accelerate development of its AI foundation models for biology and chemistry,… Read More

#News

Seed funding
#AI / data analytics / healthtech / informatics #Investment #Omics #Seed funding #SMi Systems #Start-ups

SMi discloses £6 million seed funding round

SMi Systems has disclosed a £6m ($7.6m) seed funding round to develop and prove the utility of its multi-omic platform for in vitro diagnosis and biomedical research. SMi hopes the technology will significantly accelerate the discovery of new therapeutics by biopharma companies and research institutions. Read More

#News #Start-up Zone

#Europe #Funding #Investment #Life sciences #Start-ups

European life sciences investor raises over €95 million

Vesalius Biocapital, a life sciences venture capital investor, has closed its fourth fund, Vesalius Biocapital IV, securing over €95 million of commitments. The company plans to invest in first and best-in-class European life science companies in drug development and digital health. The goal is to build a portfolio of 10-15… Read More

#Business & Investment #News #Start-up Zone